GH002: A Novel and Potent Agents for Elevating HDL-Cholesterol

Article Preview

Abstract:

The aim of this study was to evaluate whether the positive effect of GH002 on high-density lipoprotein (HDL) cholesterol in vitro and in vivo. In vitro assay, effects of GH002 on apolipoprotein (apo) A-I was studied using stable-transfected HepG2 cells with recombinant vector including apoA-I promoter; Effects of GH002 on apoA-I, apoA-II and apoC-III production were determined using HepG2 cells. In vivo assay, Effects of GH002 on lipid profile were investigated in hyperlipidemic rats. The results showed that GH002 can effectively activate apoA-I promoter, enhance apoA-I and apoA-II secretion in vitro, whereas reduce apoC-III production significantly. Furthermore, after in vivo study that the hyperlipidemic rats were treated with GH002, HDL-cholesterol levels were increased significantly (P<0.01) at 2 weeks (100 mg/kg, 28.8%) and 3 weeks (30mg/kg, 19.8% and 100mg/kg, 36.4%, respectively) compared with control group. Triglyceride levels were reduced significantly at 2 and 3 weeks (19.5%, P<0.05 and 28.1%, P<0.01 respectively). Total cholesterol levels also were reduced at 3 weeks (19.1%, P<0.05) after 100mg/kg GH002 administration, but GH002 didn’t increase the ratio of liver/body weight compared with the control group at the end of the experiments. It is therefore reasonable to assume that GH002 is an effectively HDL-cholesterol enhancer by regulating apoA-I gene expression, consequently enhancing apoA-I, apoA-II secretion and reducing apoC-III production.

You might also be interested in these eBooks

Info:

Periodical:

Pages:

337-343

Citation:

Online since:

September 2011

Authors:

Export:

Price:

[1] Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4: 193-205.

DOI: 10.1038/nrd1658

Google Scholar

[2] Spector R. Progress in the search for ideal drugs. Pharmacology 2002; 64(1): 1-7.

Google Scholar

[3] Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001; 103: 2213-2218.

DOI: 10.1161/01.cir.103.17.2213

Google Scholar

[4] Huang ZP, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clinical Science 2002; 103: 587-594.

DOI: 10.1042/cs1030587

Google Scholar

[5] Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: 11-20 (Suppl. ).

DOI: 10.1016/0021-9150(96)05852-2

Google Scholar

[6] Forte TM, McCall MR. The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis. Curr Opin Lipidol 1994; 5: 354-364.

Google Scholar

[7] Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-I. Clin Chim Acta 1999; 286(1-2): 97-114.

DOI: 10.1016/s0009-8981(99)00096-0

Google Scholar

[8] Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94: 899-903.

DOI: 10.1172/jci117412

Google Scholar

[9] Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J Lipid Res 1994; 35: 2263-2267.

DOI: 10.1016/s0022-2275(20)39932-6

Google Scholar

[10] Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high-density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994; 91: 9607-9611.

DOI: 10.1073/pnas.91.20.9607

Google Scholar

[11] Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 2007; 80(1): 1-10.

DOI: 10.1159/000102594

Google Scholar

[12] Alkhalaf M. Resveratrol-induced apoptosis is associated with activation of p.53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology 2007; 80(2-3): 134-43.

DOI: 10.1159/000103253

Google Scholar

[13] Guo L, Lian JH, Ji W, Hu WR, Wu GL, Gong BQ. Establishment of a cell-based drug screening system for identifying selective down-regulators of mPGES-1. Inflamm Res 2006; 55: 114-118.

DOI: 10.1007/s00011-005-0061-x

Google Scholar

[14] Guo L, Hu RW, Lian JH, Ji W, Deng T, Qian M, Gong BQ. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. Eur J Pharmacol 2006; 551(1-3): 80-6.

DOI: 10.1016/j.ejphar.2006.08.048

Google Scholar

[15] Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl co-enzyme A oxidase. J Clin Invest 1995; 65: 705-712.

DOI: 10.1172/jci117717

Google Scholar

[16] van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 2004; 21(9): 1531-8.

DOI: 10.1023/b:pham.0000041444.06122.8d

Google Scholar